Health Trials

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

ConditionsMelanomaNon-small Cell Lung CancerSquamous Cell Carcinoma (Skin)Renal Cell CarcinomaMerkel Cell CarcinomaTriple Negative Breast CancerHead and Neck Squamous Cell CarcinomaGastric Cancer/Gastroesophageal Junction CancerHigh Grade Serous Ovarian Carcinoma
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorAstraZeneca

About this trial

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Eligibility criteria

Qualifiers

Participant ≥ 18 year

ECOG PS of 0 to 1

Provision of 'archival' tumor specimen

At least one measurable lesion according to RECIST v1.1,

Disqualifiers

History or planned organ or allogeneic stem cell transplantation.

Active or prior documented autoimmune or inflammatory disorders, within the past 3 years

Any prior toxicities that led to permanent discontinuation of prior immunotherapy

Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anti-cancer therapy

Trial design

Treatments tested in this trial

  • AZD6750
  • rilvegostomig

Treatment groups

60 Participants
are divided into 2 treatment groups

Sponsors and collaborators

AstraZeneca

Lead sponsor

Source ClinicalTrials.gov